Bravinton

Neurology (as part of complex therapy):

as a symptomatic remedy for various forms of cerebral circulatory insufficiency (ischemic stroke, the recovery stage of hemorrhagic stroke, the consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, atherosclerosis of the cerebral vessels, post-traumatic and hypertensive encephalopathy).

Ophthalmology:

chronic vascular diseases of the choroid and retina of the eye (including occlusion of the central artery or vein of the retina),

reduced perceptual hearing acuity, Meniere's disease, idiopathic tinnitus.

acute (after the end of the course of parenteral administration of vinpocetine, as well as if parenteral administration is impossible) and chronic forms of cerebral circulatory insufficiency (including acute and residual stages of stroke, transient ischemic attacks, encephalopathy, multi-infarction dementia),

vascular diseases of the retina and / or the choroid of the eye (due to atherosclerosis, angiospasm, thrombosis),

degenerative changes in the macula of the eye caused by atherosclerosis or angiospasm,

secondary glaucoma (due to obstruction of blood vessels),

age-related vascular or toxic (drug-induced) hearing disorders,

Meniere's disease,

vertigo of labyrinth origin,

vegetative manifestations of menopausal syndrome.

hypersensitivity,

severe cardiac arrhythmias,

severe coronary heart disease,

acute phase of hemorrhagic stroke,

lactose intolerance, lactase deficiency, glucose-galactose malabsorption,

pregnancy,

lactation period,

age up to 18 years.

hypersensitivity to the drug,

severe cardiac arrhythmias,

Coronary artery disease (severe),

in the acute stage of hemorrhagic stroke,

pregnancy,

lactation period (breastfeeding).

From the CCC side: ECG changes (ST-segment depression, prolongation of the QT interval), tachycardia, extrasystole (cause-and-effect relationship is not established), blood pressure lability (more often a decrease).

From the central nervous system: sleep disorders (insomnia, increased drowsiness), dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dry mouth, nausea, heartburn.

Other: skin allergic reactions, increased sweating, hyperemia of the skin.

Decreased blood pressure, tachycardia, extrasystole, slowing of intraventricular conduction.

Currently, data on vinpocetine overdose is limited.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Symptoms: intoxication.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Improves brain metabolism by increasing the consumption of glucose and oxygen by the brain tissue. Increases the resistance of brain cells to hypoxia, facilitating the transport of oxygen and energy supply substrates to the tissues (due to a decrease in the oxygen affinity of red blood cells, increased absorption and metabolism of glucose, switching the metabolism to an energetically more favorable aerobic direction). Selectively blocks calcium-dependent PDE: increases the concentration of cAMP and cGMP in the brain. Increases the concentration of ATP and the ratio of ATP/AMP in the brain tissues, increases the exchange of norepinephrine and serotonin in the brain, has an antioxidant effect

The vasodilating effect is associated with a direct relaxing effect on the smooth muscles of the vessels, mainly of the brain. Vinpocetine does not cause the phenomenon of" stealing", first of all, it increases the blood supply to the ischemic area of the brain, without changing the blood supply to intact areas. Improves microcirculation in the brain by reducing platelet aggregation, reducing blood viscosity, and increasing the deformability of red blood cells. Increases cerebral blood flow, reduces the resistance of the brain vessels without significantly affecting the indicators of systemic circulation (blood pressure, minute volume, heart rate)

It inhibits phosphodiesterase and increases the content of cAMP in cells, which, in turn, causes a decrease in the content of calcium in the cytoplasm of smooth muscle cells and relaxation of myofibrils. A combination of vascular and metabolic effects.

Expands the blood vessels of the brain, increases blood flow, mainly in ischemic areas, improves the supply of oxygen to the brain. Promotes the utilization of glucose and increases the level of catecholamines in the central nervous system, stimulates the metabolism of norepinephrine and serotonin in the brain tissues. Reduces platelet aggregation, blood viscosity, increases the deformability of red blood cells and normalizes venous outflow against the background of a decrease in the resistance of brain vessels. Systemic blood pressure decreases slightly. It is effective in the acute period of stroke: it accelerates the regression of general cerebral and focal neurological symptoms, improves memory, attention, and intellectual productivity

In the elderly and senile age, the sensitivity of the brain vessels to the relaxing effect of vinpocetine increases, which is due to the sensitization of the adenylate cyclase-cAMP system during aging.

When taken orally, it is rapidly and completely absorbed in the gastrointestinal tract (mainly in the proximal parts of the small intestine). Bioavailability when taken on an empty stomach-about 7%. T_max vinpocetine in blood plasma-1 h, in tissues-2-4 h. When passing through the intestinal wall, it is not subjected to metabolism. When repeated doses are administered, the kinetics are linear.

Plasma protein binding-66%, clearance-66.7 l / h, exceeds hepatic clearance (50 l / h), which indicates extrahepatic metabolism. Penetrates into breast milk (0.25% within the first hour) through the placental barrier. T_1/2 vinpocetine — 4-6 hours. It is excreted by the kidneys and intestines in a ratio of 3:2.

After oral administration, vinpocetine is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 60%. C_max It is achieved after 1 h. It easily penetrates through histohematic barriers (including through the BBB) and into tissues.

T_1/2 - about 5 hours.